<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="4802a9a9-e843-46db-9d52-338895c7c538"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>Pyrimethamine Tablets, USP <br/> Rx Only<br/>
      <br/> PRESCRIBING INFORMATION<br/>
   </title>
   <effectiveTime value="20250417"/>
   <setId root="fdeff3ed-e783-411a-8317-57e8b0e931e0"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="830546433"/>
            <name>NorthStar Rx LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="650082092" root="1.3.6.1.4.1.519.1"/>
                  <name>Aurobindo Pharma Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650844777" root="1.3.6.1.4.1.519.1"/>
                        <name>APL HEALTHCARE LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72603-262" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72603-262" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3bb85f15-c8d3-4ac8-9820-b25ec1461a0a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250417"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72603-262" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Pyrimethamine<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Pyrimethamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="25" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z3614QOX8W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PYRIMETHAMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Z3614QOX8W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PYRIMETHAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72603-262-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20241001"/>
                                    <high value="20260901"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72603-262-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20241001"/>
                                    <high value="20241002"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216983" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20241001"/>
                              <high value="20260901"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>Biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="7"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="2"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">L;25</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="3bf107f6-e9cc-4cb0-9877-761d187a9035"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Pyrimethamine is an antiparasitic compound available in tablet form for oral administration. Each scored tablet contains 25 mg pyrimethamine USP and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate and pregelatinized starch (corn). <br/>
                     <br/> Pyrimethamine USP, known chemically as 5-(4- chlorophenyl)-6-ethyl-2, 4-pyrimidinediamine, has the following structural formula:</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>str</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pyrimethamine-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="a0465d0a-4a05-45a0-b632-4c9ceefe4bf0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins. </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Microbiology: </content>Pyrimethamine is a folic acid antagonist and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against <content styleCode="italics">Toxoplasma gondii. </content>
                  </paragraph>
                  <paragraph>The action of pyrimethamine against <content styleCode="italics">Toxoplasma gondii </content>is greatly enhanced when used in conjunction with sulfonamides. This was demonstrated by Eyles and Coleman<sup>1 </sup>in the treatment of experimental toxoplasmosis in the mouse. Jacobs et al<sup>2</sup> demonstrated that combination of the 2 drugs effectively prevented the development of severe uveitis in most rabbits following the inoculation of the anterior chamber of the eye with toxoplasma.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="214c7521-e368-4d2b-81ba-49c2f2cf82bd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Treatment of Toxoplasmosis: </content>Pyrimethamine tablets are indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="2ff9cb54-ff4e-4081-b913-ed798ce2bd51"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Use of pyrimethamine tablets are contraindicated in patients with known hypersensitivity to pyrimethamine or to any component of the formulation. Use of the drug is also contraindicated in patients with documented megaloblastic anemia due to folate deficiency.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="e99af480-eb53-406a-95e1-80795bdbaba6"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>The dosage of pyrimethamine required for the treatment of toxoplasmosis has a narrow therapeutic window. If signs of folate deficiency develop (see <linkHtml href="#Section_7">ADVERSE REACTIONS</linkHtml>), reduce the dosage or discontinue the drug according to the response of the patient. Folinic acid (leucovorin) should be administered in a dosage of 5 to 15 mg daily (orally, IV, or IM) until normal hematopoiesis is restored. Data in 2 humans indicate that pyrimethamine may be carcinogenic; a 51-year-old female who developed chronic granulocytic leukemia after taking pyrimethamine for 2 years for toxoplasmosis<sup>3</sup> and a 56-year-old patient who developed reticulum cell sarcoma after 14 months of pyrimethamine for toxoplasmosis.<sup>4 </sup>
                  </paragraph>
                  <paragraph>Pyrimethamine has been reported to produce a significant increase in the number of lung tumors in mice when given intraperitoneally at doses of 25 mg/kg.<sup>5 </sup>
                  </paragraph>
                  <paragraph>Pyrimethamine should be kept out of the reach of infants and children as they are extremely susceptible to adverse effects from an overdose. Deaths in pediatric patients have been reported after accidental ingestion. </paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="789f9dbc-ea1b-49d3-89d6-8c826f88c25a"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250417"/>
               <component>
                  <section ID="Section_6.1">
                     <id root="aa7ab500-728b-4cf3-a773-7aff2a18fbae"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">General:</content> A small “starting” dose for toxoplasmosis is recommended in patients with convulsive disorders to avoid the potential nervous system toxicity of pyrimethamine. Pyrimethamine should be used with caution in patients with impaired renal or hepatic function or in patients with possible folate deficiency, such as individuals with malabsorption syndrome, alcoholism, or pregnancy, and those receiving therapy, such as phenytoin, affecting folate levels (see Pregnancy subsection).</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="3505e38d-c7d8-4277-a568-4f2e7677ddfc"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Information for Patients:</content> Patients should be warned that at the first appearance of a skin rash they should stop use of pyrimethamine and seek medical attention immediately. Patients should also be warned that the appearance of sore throat, pallor, purpura, or glossitis may be early indications of serious disorders which require treatment with pyrimethamine to be stopped and medical treatment to be sought. </paragraph>
                        <br/>
                        <paragraph>Women of childbearing potential who are taking pyrimethamine should be warned against becoming pregnant. Patients should be warned to keep pyrimethamine out of the reach of children. Patients should be advised not to exceed recommended doses. Patients should be warned that if anorexia and vomiting occur, they may be minimized by taking the drug with meals. Concurrent administration of folinic acid is strongly recommended when used for the treatment of toxoplasmosis in all patients.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.3">
                     <id root="f83e98e4-5c09-4b27-bd9f-de64b1b44f55"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Laboratory Tests:</content> In patients receiving high dosage, semiweekly blood counts, including platelet counts, should be performed. </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="6a026c05-32b9-4585-88cd-54d1bb5aae54"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Drug Interactions:</content> Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see <linkHtml href="#Section_5">WARNINGS</linkHtml>). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="ec17e689-3d3e-43b0-bbdf-f10a26b212d8"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</content> See WARNINGS section for information on carcinogenesis.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="3fbac4f1-3aa4-4c89-b101-9133890047e3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="italics"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">Mutagenesis:</content>
                           </content> Pyrimethamine has been shown to be nonmutagenic in the following <content styleCode="italics">in vitro </content>assays: the Ames point mutation assay, the Rec assay, and the <content styleCode="italics">E. coli </content>WP2 assay. It was positive in the L5178Y/TK +/- mouse lymphoma assay in the absence of exogenous metabolic activation.<sup>6 </sup>Human blood lymphocytes cultured <content styleCode="italics">in vitro </content>had structural chromosome aberrations induced by pyrimethamine. <content styleCode="italics">In vivo, </content>chromosomes analyzed from the bone marrow of rats dosed with pyrimethamine showed an increased number of structural and numerical aberrations.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.8">
                     <id root="33b024a9-9423-4091-9cfa-a7bb16a4a042"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pregnancy:<content styleCode="italics"> Teratogenic Effects: </content>
                           </content>Pyrimethamine has been shown to be teratogenic in rats when given in oral doses 2.5 times the human dose for treatment of toxoplasmosis. At these doses in rats, there was a significant increase in abnormalities such as cleft palate, brachygnathia, oligodactyly, and microphthalmia. Pyrimethamine has also been shown to produce terata such as meningocele in hamsters and cleft palate in miniature pigs when given in oral doses 5 times the human dose for the treatment of toxoplasmosis. </paragraph>
                        <br/>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women. Pyrimethamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </paragraph>
                        <br/>
                        <paragraph>Concurrent administration of folinic acid is strongly recommended when used during pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="20f5972c-c9ae-4e76-ad0e-2f5f4dc0a161"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Nursing Mothers:</content> Pyrimethamine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pyrimethamine and from concurrent use of a sulfonamide with pyrimethamine for treatment of some patients with toxoplasmosis, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see <linkHtml href="#Section_5">WARNINGS</linkHtml> and <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>: Pregnancy).</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="62d2262f-0f4b-454e-90b2-49a38e046c9e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric Use:</content> See DOSAGE AND ADMINISTRATION section.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.11">
                     <id root="75625d3f-e283-4f35-a615-6a05fcd5e0f2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Geriatric Use:</content> Clinical studies of pyrimethamine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="2ea816e0-6045-4c07-b724-b4286030e5f4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Hypersensitivity reactions, occasionally severe (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. Consult the complete prescribing information for the relevant sulfonamide for sulfonamide-associated adverse events. With doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. Vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. Doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. </paragraph>
                  <br/>
                  <paragraph>Hematologic effects, however, may also occur at low doses in certain individuals (see <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>; <linkHtml href="#Section_6.1">General</linkHtml>). Pulmonary eosinophilia has been reported rarely.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="6880b803-ec06-4f7f-8acf-07f884a139b3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Following the ingestion of 300 mg or more of pyrimethamine, gastrointestinal and/or central nervous system signs may be present, including convulsions. The initial symptoms are usually gastrointestinal and may include abdominal pain, nausea, severe and repeated vomiting, possibly including hematemesis. Central nervous system toxicity may be manifest by initial excitability, generalized and prolonged convulsions which may be followed by respiratory depression, circulatory collapse, and death within a few hours. Neurological symptoms appear rapidly (30 minutes to 2 hours after drug ingestion), suggesting that in gross overdosage pyrimethamine has a direct toxic effect on the central nervous system. </paragraph>
                  <br/>
                  <paragraph>The fatal dose is variable, with the smallest reported fatal single dose being 375 mg. There are, however, reports of pediatric patients who have recovered after taking 375 to 625 mg. </paragraph>
                  <br/>
                  <paragraph>There is no specific antidote to acute pyrimethamine poisoning. In the event of overdosage, symptomatic and supportive measures should be employed. Gastric lavage is recommended and is effective if carriedout very soon after drug ingestion. Parenteral diazepam may be used to control convulsions. Folinic acid should be administered within 2 hours of drug ingestion to be most effective in counteracting the effects on the hematopoietic system (see WARNINGS). Due to the long half-life of pyrimethamine, daily monitoring of peripheral blood counts is recommended for up to several weeks after the overdose until normal hematologic values are restored.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="7baa758e-f99a-4d1f-b487-c0fb73222615"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">For Treatment of Toxoplasmosis: </content>The dosage of pyrimethamine tablets for the treatment of toxoplasmosis must be carefully adjusted so as to provide maximum therapeutic effect and a minimum of side effects. At the dosage required, there is a marked variation in the tolerance to the drug. Young patients may tolerate higher doses than older individuals. Concurrent administration of folinic acid is strongly recommended in all patients. </paragraph>
                  <br/>
                  <paragraph>The adult <content styleCode="italics">starting </content>dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g. sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy. The dosage may then be reduced to about one half that previously given for each drug and continued for an additional 4 to 5 weeks. </paragraph>
                  <br/>
                  <paragraph>The pediatric dosage of pyrimethamine tablets is 1 mg/kg/day divided into 2 equal daily doses; after 2 to 4 days this dose may be reduced to one half and continued for approximately 1 month. The usual pediatric sulfonamide dosage is used in conjunction with pyrimethamine tablets.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="1631d1d2-d97b-4c11-97d5-f064473012d1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED:</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pyrimethamine Tablets USP, 25 mg </content>are white to off-white round shaped, biconvex, uncoated tablet, debossed with ‘L’ ‘25’ on one side and break line on other side. They are supplied as follows:</paragraph>
                  <paragraph>            Bottles of 30                                 NDC 72603-262-01</paragraph>
                  <paragraph>            Bottles of 100                               NDC 72603-262-02</paragraph>
                  <br/>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature] <content styleCode="bold">in a dry place and protect from light. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="14a291dd-c16f-4223-8420-8591e9f377f5"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Eyles DE, Coleman N. Synergistic effect of sulfadiazine and Daraprim against experimental toxoplasmosis in the mouse. <content styleCode="italics">Antibiot Chemother </content>1953;3:483-490. </item>
                     <item>Jacobs L, Melton ML, Kaufman HE. Treatment of experimental ocular toxoplasmosis. <content styleCode="italics">Arch Ophthalmol. </content>1964;71:111-118. </item>
                     <item>Jim RTS, Elizaga FV. Development of chronic granulocytic leukemia in a patient treated with pyrimethamine. <content styleCode="italics">Hawaii Med J. </content>1977;36:173-176. </item>
                     <item>Sadoff L. Antimalarial drugs and Burkitt’s lymphoma. <content styleCode="italics">Lancet. </content>1973;2:1262-1263. </item>
                     <item>Bahna L. Pyrimethamine. <content styleCode="italics">LARC Monogr Eval Carcinog Risk Chem. </content>1977;13:233-242. </item>
                     <item> Clive D, Johnson KO, Spector JKS, et al. Validation and characterization of the L5178Y/TK +/- mouse lymphoma mutagen assay system. <content styleCode="italics">Mut Res. </content>1979;59:61-108.</item>
                  </list>
                  <paragraph>Manufactured for: Northstar Rx LLC<br/>                             Memphis, TN 38141.<br/>
                     <br/> Manufactured by: APL Health Care Limited, Unit-I<br/>                             SEZ, Mahabubnagar (Dt)-509302<br/>                             India.<br/>
                     <br/> M.L.No.: 16/MN/TS/2014/F/G<br/>
                     <br/> Issued: 05/2024 </paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="52ea555d-6a6e-44ef-a032-ec873b2d0feb"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 25 mg (30 Tablets Bottle)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only<br/>
                        <br/>
                     </content>NDC 72603-<content styleCode="bold">262</content>-01<br/>
                     <content styleCode="bold">
                        <br/> Pyrimethamine Tablets, USP<br/> 25 mg<br/>
                     </content>
                     <content styleCode="bold">
                        <br/> Warning:</content> Potent Drug - do not exceed<br/> recommended dosage.<br/>
                     <content styleCode="bold">
                        <br/> 30 Tablets<br/>
                        <br/> NORTHSTAR<sup>®</sup>
                        <br/>
                        <br/>
                        <renderMultiMedia referencedObject="MM2"/>
                        <br/>
                        <br/>
                     </content>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 25 mg (30 Tablets Bottle)</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pyrimethamine-fig1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>